Research Article
Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome
Table 3
Follow-up after PFO closure.
| Characteristic | Before PS matching | After PS matching | All | Gr short | Gr long | | Gr short | Gr long | | N = 259 | N = 88 | N = 171 | value | N = 86 | N = 86 | value |
| Duration of antithrombotic therapy (days) | median [IQR] | 587 [194–2856] | 184 [181–194] | 1519 [594–3987] | <0.001 | 184 [181–194] | 2390 [702–4172] | <0.001 | Duration of aspirin | median [IQR] | 630 [194–2315] | 184 [181–194] | 1324 [623–3007] | | 184 [181–194] | 2125 [692–3307] | | Duration of clopidogrel | median [IQR] | 434 [222–837] | 184 | 635 [381–2372] | | 184 | 529 [376–683] | | Duration of dual antiplatelet therapy | median [IQR] | 370 [194–4330] | 184 [180–197] | 4036 [496–5322] | | 184 [180–199] | 4238 [858–5399] | | Duration of anticoagulants | median [IQR] | 185 | 185 | — | | 185 | — | | Duration of aspirin + anticoagulants | median [IQR] | 3711 [2221–5201] | — | 3711 [2221–5201] | | — | 3711 [2221–5201] | | Duration of follow-up (years) | median [IQR] | 10 [4–13] | 10 [4–14] | 9 [3–13] | 0.52 | 10 [4–14] | 11 [6–14] | 0.16 | Major adverse events | | | | | | | | | Death | n (%) | 4 (1.5) | 0 (0) | 4 (2.3) | 0.15 | 0 (0) | 1 (1) | 0.32 | Cardiovascular death | n (%) | 1 (0.4) | 0 (0) | 1 (0.6) | 1.00 | 0 (0) | 0 (0) | — | Stroke | n (%) | 7 (3) | 2 (3) | 5 (3) | 0.83 | 2 (2) | 3 (3) | 1.00 | Ischemic stroke | n (%) | 8 (3) | 3 (3) | 5 (3) | 0.83 | 3 (3) | 3 (3) | 1.00 | Hemorrhagic stroke | n (%) | 0 (0) | 0 (0) | 0 (0) | — | 0 (0) | 0 (0) | — | Cryptogenic stroke | n (%) | 4 (2) | 1 (1) | 3 (2) | 0.70 | 1 (1) | 2 (2) | 0.56 | Major bleeding | n (%) | 0 (0) | 0 (0) | 0 (0) | — | 0 (0) | 0 (0) | — | Other adverse events | | | | | | | | | Minor bleeding | n (%) | 48 (19) | 13 (15) | 35 (20) | 0.27 | 12 (14) | 19 (22) | 0.17 | BARC-1 | n (%) | 44 (17) | 12 (14) | 32 (19) | 0.38 | 11 (13) | 16 (19) | 0.40 | BARC-2 | n (%) | 4 (2) | 1 (1) | 3 (2) | 1.00 | 1 (1) | 3 (3) | 0.62 | Transient ischemic attack | n (%) | 9 (3) | 3 (3) | 6 (4) | 1.00 | 3 (3) | 3 (3) | 1.00 | Atrial fibrillation (paroxysmal) | n (%) | 17 (7) | 3 (3) | 14 (8) | 0.18 | 3 (3) | 7 (8) | 0.33 |
|
|
Gr = Group; IQR = interquartile range; PS = propensity score.
|